PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role

Lipoprotein (a) [Lp(a)] is independently associated with CVD risk. Evolocumab, a monoclonal antibody (mAb) to proprotein convertase subtilisin/kexin type 9 (PCSK9), decreases Lp(a). The potential mechanisms were assessed. A pooled analysis of Lp(a) and LDL cholesterol (LDL-C) in 3,278 patients from...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Lipid Res
Main Authors: Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society for Biochemistry and Molecular Biology 2016
Assuntos:
Patient-Oriented and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878192/
https://ncbi.nlm.nih.gov/pubmed/27102113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.P065334
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados